Last reviewed · How we verify
Selectol (CELIPROLOL)
At a glance
| Generic name | CELIPROLOL |
|---|---|
| Drug class | celiprolol |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Angina pectoris
- Hypertensive disorder
Common side effects
Key clinical trials
- Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome (PHASE3)
- Chronic Beta-blockade and Cardiopulmonary Exercise in COPD (PHASE4)
- Celiprolol Versus Ditiazem for the Prevention of Postoperative Cardiac Arrythmias in Thoracic Surgery (PHASE2)
- Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selectol CI brief — competitive landscape report
- Selectol updates RSS · CI watch RSS